Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft Versus Host Disease
Hematopoietic Stem Cell Transplantation
Leukemia

Interventions

DRUG: Efprezimod alfa
DRUG: Methotrexate
DRUG: Tacrolimus
DRUG: Placebo

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]